3 Months Versus 12 Months Dual Antiplatelet Therapy After Drug-eluting Stent Implantation in STEMI
NCT ID: NCT04570345
Last Updated: 2020-12-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
1002 participants
INTERVENTIONAL
2021-01-01
2022-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ticagrelor monotherapy
Ticagrelor monotherapy after 3-month DAPT(aspirin with ticagrelor)
ticagrelor monotherapy
• Drug: ticagrelor monothearpy after first 3 months dual therapy
Aspirin with P2Y12 receptor inhibitor
Aspirin with P2Y12 receptor inhibitor after 3-month DAPT(aspirin with ticagrelor)
ticagrelor monotherapy
• Drug: ticagrelor monothearpy after first 3 months dual therapy
Aspirin with P2Y12 receptor inhibitor
• Drug: aspirin plus ticagrelor dual therapy during 12 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ticagrelor monotherapy
• Drug: ticagrelor monothearpy after first 3 months dual therapy
Aspirin with P2Y12 receptor inhibitor
• Drug: aspirin plus ticagrelor dual therapy during 12 months
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who received new generation sirolimus-eluting (Osiro®) stent implantation for treating ACS
* Provision of informed consent
Exclusion Criteria
* Pregnant women or women with potential childbearing
* Life expectancy \< 1 year
19 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dong-A University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kyungil Park
Associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kyungil Park, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Dong-A University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Internal Medicine,Dong-A University College of Medicine
Busan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Kyungil Park, MD
Role: primary
YoungRak Cho, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DAUHIRB-20-162
Identifier Type: -
Identifier Source: org_study_id